Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C.
Ann Intern Med. 2023 Feb;176(2):182-195. doi: 10.7326/M22-0684. Epub 2023 Jan 3.
Long-Term Treatment of Postmenopausal Osteoporosis.
Brown JP.
Endocrinol Metab (Seoul). 2021 Jun;36(3):544-552. doi: 10.3803/EnM.2021.301. Epub 2021 Jun 22.
Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society.
[No authors listed]
Menopause. 2021 Sep 1;28(9):973-997. doi: 10.1097/GME.0000000000001831.
T-Cell Mediated Inflammation in Postmenopausal Osteoporosis.
Wu D, Cline-Smith A, Shashkova E, Perla A, Katyal A, Aurora R.
Front Immunol. 2021 Jun 30;12:687551. doi: 10.3389/fimmu.2021.687551. eCollection 2021.
Osteoporosis.
Ensrud KE, Crandall CJ.
Ann Intern Med. 2017 Aug 1;167(3):ITC17-ITC32. doi: 10.7326/AITC201708010.
Management of Postmenopausal Osteoporosis: ACOG Clinical Practice Guideline No. 2.
ACOG Committee on Clinical Practice Guidelines–Gynecology.
Obstet Gynecol. 2022 Apr 1;139(4):698-717. doi: 10.1097/AOG.0000000000004730.
Osteoporosis. Definition and clinical presentation.
Glaser DL, Kaplan FS.
Spine (Phila Pa 1976). 1997 Dec 15;22(24 Suppl):12S-16S. doi: 10.1097/00007632-199712151-00003.
Immunoporosis: Role of immune system in the pathophysiology of different types of osteoporosis.
Zhang W, Gao R, Rong X, Zhu S, Cui Y, Liu H, Li M.
Front Endocrinol (Lausanne). 2022 Sep 6;13:965258. doi: 10.3389/fendo.2022.965258. eCollection 2022.
Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y.
Sci Rep. 2021 Jun 3;11(1):11801. doi: 10.1038/s41598-021-91248-6.
Primary hyperparathyroidism and osteoporosis.
Mazzuoli GF, D'Erasmo E, Pisani D.
Aging (Milano). 1998 Jun;10(3):225-31. doi: 10.1007/BF03339656.
